In Veritas enlists Utek to seek new technologies for patient monitoring:
This article was originally published in Clinica
In Veritas Medical Diagnostics has entered a strategic alliance with technology transfer company Utek in which the latter will help the Inverness, Scotland-based firm to identify new technologies to add to its patient testing and monitoring portfolio. In Veritas is currently developing a device for measuring coagulation blood in patients with cardiovascular disorders, as well as a product that predicts for pregnant women the onset of labour up to several weeks before birth. Tampa, Florida-based Utek helps companies, in exchange for equity, to acquire innovative technologies emerging from universities and laboratory research centres.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.